Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $510.00 price target on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. Chardan Capital lowered their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Wells Fargo & Company lowered their price objective on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Finally, Morgan Stanley dropped their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $468.84.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $328.70 on Wednesday. The company has a market cap of $43.59 billion, a P/E ratio of 192.22 and a beta of 0.36. The company has a fifty day simple moving average of $332.13 and a 200 day simple moving average of $402.21. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.65) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This trade represents a 9.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,923 shares of company stock valued at $18,072,087 in the last three months. 1.50% of the stock is owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $25,000. Salomon & Ludwin LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $27,000. Finally, Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and set a $510 price target, signaling sizable upside vs. the current share price. Article Title
• Positive Sentiment: Needham’s Joseph Stringer maintained a Buy rating and a $510 target, citing underpenetrated TTR market opportunity and commercial momentum. Article Title
• Positive Sentiment: Bank of America reiterated a Buy stance, highlighting durable ATTR growth and Amvuttra commercial momentum as upside drivers. Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating with a $425 price target, reinforcing upside expectations from sell‑side analysts. Article Title
• Positive Sentiment: Alnylam announced a strategic collaboration with Viz.ai and support for the American Heart Association to advance earlier identification and care coordination for ATTR‑CM — a potential tailwind for market penetration and patient flow into Alnylam’s TTR treatments. Article Title
• Neutral Sentiment: A recent company transcript reviews strategy and progress in transforming ATTR care (useful for qualitative context but no new financials). Article Title
• Neutral Sentiment: Multiple news items report a rise in short‑interest figures but the publicly posted values show zeros/NaN and appear inconsistent — the data currently looks unreliable and likely isn’t driving the move. (Various short‑interest reporting entries)
• Negative Sentiment: On Feb. 12 Alnylam missed the quarter’s EPS estimate ($1.25 vs. $1.43) and posted revenue below consensus ($1.10B vs. $1.16B), a reminder that execution and near‑term results can still disappoint despite bullish sentiment; this remains a downside risk if future quarters miss expectations.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.